Navitoclax (ABT-263)

For research use only.

Catalog No.S1001

186 publications

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Navitoclax (ABT-263) has been cited by 186 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHscFVnUUN3ME2wMlAxPjZ7IN88US=> Mm\uV2FPT0WU
MV-4-11 NWnhN2dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD1yLkCxOVg3KM7:TR?= MV7TRW5ITVJ?
NKM-1 NX7sXYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCbXVKSzVyPUCuNFE3QTlizszN NF7sXFhUSU6JRWK=
ML-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3YTWM2OD1yLkCxPVg{KM7:TR?= MmXaV2FPT0WU
BV-173 NHnyZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnl[4hKSzVyPUCuNFI{OTRizszN NF;3UFNUSU6JRWK=
RS4-11 NIS4RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTwfWlKSzVyPUCuNFI2QDdizszN NGCzXWZUSU6JRWK=
HL-60 NHq3SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\pWGlEPTB;MD6wNlkxQCEQvF2= NFX4R21USU6JRWK=
KY821 NYHzbWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEK5O|Uh|ryP NFzYSphUSU6JRWK=
ECC10 NF;vR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[z[I9KSzVyPUCuNFM4QTJizszN Mn;vV2FPT0WU
NCI-H720 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O2TWlEPTB;MD6wOFAyOSEQvF2= NYXMd|VKW0GQR1XS
QIMR-WIL NG\OZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMESyPFch|ryP MVHTRW5ITVJ?
KG-1 NFP0U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjCfoRKSzVyPUCuNFQ1QDZizszN NYryNFBKW0GQR1XS
TGW MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjNSm54UUN3ME2wMlA1PjN|IN88US=> NX7YfplUW0GQR1XS
ATN-1 NFXDXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXGO5pKSzVyPUCuNFQ4OzNizszN MY\TRW5ITVJ?
RH-18 NVXTO5duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwME[wOFgh|ryP NXuwPYNGW0GQR1XS
EW-18 NEC5eJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwME[4OFEh|ryP M1TPVXNCVkeHUh?=
NB17 NXLRd3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfFbmtiUUN3ME2wMlA4OTJ2IN88US=> NEniSHBUSU6JRWK=
SK-NEP-1 NYS2eZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3DW5NKSzVyPUCuNFczOTNizszN M{OydnNCVkeHUh?=
P12-ICHIKAWA NHfHUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXNfFJ7UUN3ME2wMlA4Pzd6IN88US=> M3zYPXNCVkeHUh?=
KARPAS-45 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HBeGlEPTB;MD6wO|gyPSEQvF2= NFPlRlJUSU6JRWK=
EW-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn75TWM2OD1yLkC4NFU{KM7:TR?= M4qxWXNCVkeHUh?=
NB13 NFu0UFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MontTWM2OD1yLkC4NlA{KM7:TR?= MXvTRW5ITVJ?
NCI-H209 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEi3NFQh|ryP NVS2SXlpW0GQR1XS
NCI-H1092 NX7O[WRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XGZmlEPTB;MD6xNFI4PSEQvF2= M37DUXNCVkeHUh?=
NH-12 NHP2T|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXLR29KSzVyPUCuNVA4PDRizszN NXT1c4VjW0GQR1XS
697 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K0VWlEPTB;MD6xNFg{QSEQvF2= NHvJeGRUSU6JRWK=
KE-37 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37y[GlEPTB;MD6xNVM4KM7:TR?= MVvTRW5ITVJ?
MOLT-4 M1eyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMUWxOlkh|ryP M2jyXHNCVkeHUh?=
CHP-134 NVjuWZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTZXWxIUUN3ME2wMlE3OzB4IN88US=> MnrEV2FPT0WU
D-283MED MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L2ZWlEPTB;MD6xO|Y5PiEQvF2= M2\PbnNCVkeHUh?=
LU-135 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILKVGlKSzVyPUCuNVg2PTJizszN NGHTNXFUSU6JRWK=
LU-134-A NH25VI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrqbVhmUUN3ME2wMlE5PjdzIN88US=> NYXJTnNqW0GQR1XS
EM-2 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e0O2lEPTB;MD6xPVkyQCEQvF2= M4jJV3NCVkeHUh?=
LU-139 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMkC0PVgh|ryP MUDTRW5ITVJ?
ALL-PO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMkG5PFgh|ryP MlOwV2FPT0WU
NB12 NH7HO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64XXNCUUN3ME2wMlI{OTF3IN88US=> M2TTTXNCVkeHUh?=
KP-N-YN NEnYWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzwU2JoUUN3ME2wMlI{PTd|IN88US=> M1\yNnNCVkeHUh?=
BEN M2HPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMkO5Olgh|ryP MUDTRW5ITVJ?
HCC1569 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF25dpVKSzVyPUCuNlUyODZizszN M{nnbnNCVkeHUh?=
HuO9 NYfPXXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMfm5mUUN3ME2wMlI3PzF3IN88US=> NIDyephUSU6JRWK=
WM-115 NF\sSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6zepVKSzVyPUCuNlc4OzhizszN M3\mfHNCVkeHUh?=
CCRF-CEM NVTiTmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nLN2lEPTB;MD6zN|UzQSEQvF2= NUDqboozW0GQR1XS
IST-SL1 NHHzfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfMTWM2OD1yLkO1N|Q{KM7:TR?= NYK4cpc3W0GQR1XS
BE-13 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1yLkO2OFU6KM7:TR?= NX60SWVLW0GQR1XS
COR-L88 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwM{[1OEDPxE1? NIC5RlNUSU6JRWK=
DOHH-2 NF7LdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DuZWlEPTB;MD60NVAzOyEQvF2= MnKxV2FPT0WU
A704 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwNEK2O{DPxE1? NYPp[4ZoW0GQR1XS
KNS-81-FD NIXOOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrISFJzUUN3ME2wMlQ1ODF5IN88US=> MUPTRW5ITVJ?
RPMI-8226 M{HJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyzZ|hKSzVyPUCuOFU3PTJizszN MnKyV2FPT0WU
TGBC24TKB MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf2e3RKSzVyPUCuOFU4PzhizszN MoPTV2FPT0WU
NCI-H1304 NXfkbZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfXZ2RKSzVyPUCuOFYyPTdizszN MWXTRW5ITVJ?
MOLT-13 M{\MPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXtbHhxUUN3ME2wMlQ3PjF|IN88US=> M4L3VXNCVkeHUh?=
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[0TWM2OD1yLkS2OlcyKM7:TR?= MnLZV2FPT0WU
MS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfjSIVuUUN3ME2wMlQ3QTN|IN88US=> MV;TRW5ITVJ?
RMG-I NVTBW2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNEm0OlQh|ryP NHPvSphUSU6JRWK=
NTERA-S-cl-D1 NXntbJlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwNUCwNVkh|ryP MkLpV2FPT0WU
NCI-H1048 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDGTWM2OD1yLkWwPVU{KM7:TR?= M4j3bHNCVkeHUh?=
SW1417 NGjIS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNUW0N|gh|ryP NU\zWIFvW0GQR1XS
DB Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\zNGlEPTB;MD61O|A5KM7:TR?= MVLTRW5ITVJ?
MEG-01 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDvZohKSzVyPUCuOVg{OiEQvF2= M{HIVnNCVkeHUh?=
EW-13 NIi3NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNUizOFEh|ryP M{HFbXNCVkeHUh?=
LAMA-84 M3vEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNUmyNFch|ryP NUKyRZdQW0GQR1XS
J-RT3-T3-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli4TWM2OD1yLk[wPFA5KM7:TR?= M{\xO3NCVkeHUh?=
MOLT-16 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f5e2lEPTB;MD62OVI3PCEQvF2= NWXEbYJyW0GQR1XS
DU-4475 M4HrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW4PVVMUUN3ME2wMlY2PDJ5IN88US=> MoDoV2FPT0WU
HAL-01 M3fGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ewbmlEPTB;MD63NlU1QSEQvF2= M1zNO3NCVkeHUh?=
RD M1K5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnkN|ZKSzVyPUCuO|U5QTlizszN MX7TRW5ITVJ?
OAW-28 NXr4OpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzkTWM2OD1yLke4N|ch|ryP MnjwV2FPT0WU
HCC38 NF3G[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwOECxPUDPxE1? MnWwV2FPT0WU
NMC-G1 Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fmXGlEPTB;MD64NVEzOSEQvF2= MlvRV2FPT0WU
EW-16 M{\VSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHWTWM2OD1yLkixN|I5KM7:TR?= MVTTRW5ITVJ?
DU-145 NUfmcY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7LTWM2OD1yLki5PVI{KM7:TR?= M1;1dXNCVkeHUh?=
HPAF-II M1\LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm1[WpKSzVyPUCuPVI3OjhizszN MUfTRW5ITVJ?
A427 NYXDT|diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwOUOwNlIh|ryP MYDTRW5ITVJ?
PA-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\3TWM2OD1yLkm1OlQzKM7:TR?= M1y0XXNCVkeHUh?=
OAW-42 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKzTWM2OD1yLkm2NVQ3KM7:TR?= NV7PSFgxW0GQR1XS
L-428 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\WTWM2OD1zLkCxNlUh|ryP MnLhV2FPT0WU
COLO-824 NIrEV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjtTWM2OD1zLkCxO|A5KM7:TR?= M3;uOXNCVkeHUh?=
P30-OHK NFnnSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n6cGlEPTB;MT6wOFY5QCEQvF2= NVKxdI5UW0GQR1XS
NCI-H2170 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPoTWM2OD1zLkC2NlMh|ryP MWrTRW5ITVJ?
HCC2998 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\HOVVCUUN3ME2xMlA4OTN3IN88US=> NUO5RVlHW0GQR1XS
NB14 NF[wRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP3d3lMUUN3ME2xMlE{PzR6IN88US=> MlHyV2FPT0WU
TGBC1TKB M1Gxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwMUSxOVIh|ryP M3TOdnNCVkeHUh?=
KP-N-YS NWLmbmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPaSlRKSzVyPUGuNVYzOzZizszN NYXIWYN2W0GQR1XS
CAL-120 NG\adYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjHbIZKSzVyPUGuNVY1OjlizszN NIXnRoJUSU6JRWK=
SBC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TuemlEPTB;MT6xPVA2OyEQvF2= M1\iVnNCVkeHUh?=
C32 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz6WI9GUUN3ME2xMlE6ODh6IN88US=> NGHOSVdUSU6JRWK=
HCC2157 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULuVGkxUUN3ME2xMlE6PDl2IN88US=> NWTQfWhiW0GQR1XS
COLO-792 NV\Xe3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jRRWlEPTB;MT6yNFA4OSEQvF2= MmTUV2FPT0WU
ES7 M3;OWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLhUmc1UUN3ME2xMlI4QTVzIN88US=> NUPvVZJSW0GQR1XS
HEL NWLoNJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHEWJJKSzVyPUGuN|ExOjlizszN M3rHb3NCVkeHUh?=
ES4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwM{S5PVgh|ryP NXPmSYtmW0GQR1XS
NCI-SNU-1 NUDqT29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwM{[1OVUh|ryP NYSyPHJzW0GQR1XS
MDA-MB-415 NYWxd4FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4njNmlEPTB;MT6zPFg2KM7:TR?= MX;TRW5ITVJ?
NCI-H2342 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHBNldKSzVyPUGuOFAzPjlizszN MYHTRW5ITVJ?
NB69 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrk[5JTUUN3ME2xMlQ3OjdzIN88US=> NYrweWx[W0GQR1XS
D-247MG NU\ZPZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwNUGxNlIh|ryP NV60TJJtW0GQR1XS
SCC-4 NIjDcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fJcGlEPTB;MT61PVg5PyEQvF2= NHy2UnFUSU6JRWK=
HuH-7 NVfidpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfjPJdKSzVyPUGuOlczQTNizszN NFTYRVNUSU6JRWK=
A388 M3XacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWyeJRKSzVyPUGuOlg4OjRizszN M1nj[nNCVkeHUh?=
Calu-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnyTWM2OD1zLkewOlk4KM7:TR?= MYDTRW5ITVJ?
NCI-H1648 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj5TWM2OD1zLkexOFE5KM7:TR?= M4fPPXNCVkeHUh?=
NCI-H2052 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwN{KyNFEh|ryP NF;FdHBUSU6JRWK=
Ramos-2G6-4C10 M4rPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwN{O2OVYh|ryP M4qwSHNCVkeHUh?=
DEL NF\1[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LLPGlEPTB;MT63OFY6OiEQvF2= MlzSV2FPT0WU
SNU-423 MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofvTWM2OD1zLke4NVU4KM7:TR?= NHP3T3dUSU6JRWK=
COR-L23 NYrUW4VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwN{m4O|Qh|ryP MkXiV2FPT0WU
OMC-1 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv0TWM2OD1zLki2NFE3KM7:TR?= NW\NfIpQW0GQR1XS
EW-11 NUjzcI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj6VnByUUN3ME2xMlk2PjV5IN88US=> Mny2V2FPT0WU
HSC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXJbnR4UUN3ME2xMlk3OzZ3IN88US=> MWTTRW5ITVJ?
MLMA MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwOU[2O|ch|ryP NVvXfWhSW0GQR1XS
RCM-1 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJTWM2OD1{LkCwN|k6KM7:TR?= Moj6V2FPT0WU
MFE-280 NHLzUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMEK4OFgh|ryP NY\vXJpnW0GQR1XS
ES8 M3fyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHodIdpUUN3ME2yMlI2PDdzIN88US=> M3\2RnNCVkeHUh?=
TE-11 M1PUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPaTWM2OD1{LkK5OFc{KM7:TR?= NVrSXGlrW0GQR1XS
HuO-3N1 NETHdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJwNEi3PEDPxE1? MoPIV2FPT0WU
MHH-NB-11 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jreWlEPTB;Mj61NVE2QCEQvF2= NH;tcm5USU6JRWK=
TGBC11TKB NGjQO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjvUVBKSzVyPUKuOVc3QDFizszN NWTlWoRSW0GQR1XS
HOP-92 NYX2R2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImwSnRKSzVyPUKuOVg4PDNizszN M{PkfHNCVkeHUh?=
IGR-1 M{TEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwNkKwN|Uh|ryP NEfWO2dUSU6JRWK=
GOTO NGfZVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfKTWM2OD1{Lk[1N|c4KM7:TR?= M1fiUHNCVkeHUh?=
NCI-H1650 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvUTWM2OD1{LkeyNlE2KM7:TR?= Ml;pV2FPT0WU
NCI-H1581 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rxfWlEPTB;Mj63PVY5OSEQvF2= M3vxUHNCVkeHUh?=
NCI-H2405 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLRZnhEUUN3ME2yMlgzPzh{IN88US=> M1jRe3NCVkeHUh?=
U-118-MG NEK1O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwOU[0PVEh|ryP NYX5VIFjW0GQR1XS
DoTc2-4510 M2[0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj5emVKSzVyPUOuNFE1OTdizszN M2fhdXNCVkeHUh?=
NCI-H596 M1m4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\0OItKSzVyPUOuNFQ6QTdizszN MX7TRW5ITVJ?
MPP-89 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\N[nRCUUN3ME2zMlA2PjZ4IN88US=> NE\iS|FUSU6JRWK=
GCIY Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzNNpM1UUN3ME2zMlIxPDlzIN88US=> M2rlc3NCVkeHUh?=
SW626 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jB[2lEPTB;Mz6yOFU1OyEQvF2= MUnTRW5ITVJ?
OCI-AML2 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2POV2lEPTB;Mz6zNVI4OiEQvF2= MVLTRW5ITVJ?
NBsusSR MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXUN2xKSzVyPUOuN|Q6OzhizszN MnLnV2FPT0WU
AN3-CA NWXMd4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDPTWM2OD1|LkS0NlM5KM7:TR?= MlzVV2FPT0WU
EFM-19 M4LITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqxTWM2OD1|LkS4N|M6KM7:TR?= MoX5V2FPT0WU
RVH-421 NGPRWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwNU[4O|ch|ryP MWXTRW5ITVJ?
5637 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHYPXVWUUN3ME2zMlYyOTB|IN88US=> M4fWRXNCVkeHUh?=
PANC-08-13 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS0TWM2OD1|Lk[zOFczKM7:TR?= NVn4doJnW0GQR1XS
H9 NFS4c|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNwNkexOFQh|ryP NFfJUWFUSU6JRWK=
KARPAS-299 NY\HNVdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\FdotKSzVyPUOuOlc{PjFizszN MnrqV2FPT0WU
TE-5 NVT4Vm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\vb|ZqUUN3ME2zMlcxPzB7IN88US=> NHP4c|NUSU6JRWK=
NOS-1 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5VY1KSzVyPUOuO|k5OzRizszN MkHOV2FPT0WU
HH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\XeHZqUUN3ME2zMlg{QDZ6IN88US=> NVXPNVloW0GQR1XS
769-P M{nUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LSWmlEPTB;Mz64PVUyKM7:TR?= M2rCcnNCVkeHUh?=
CHP-212 M4TF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fDOGlEPTB;Mz65NlU1QSEQvF2= MlzuV2FPT0WU
NCI-H82 M{mzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDQTWM2OD1|Lkm1PVM3KM7:TR?= MX3TRW5ITVJ?
Mo-T Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XncGlEPTB;ND6wOFMyOiEQvF2= NHnHb3RUSU6JRWK=
BB65-RCC NIjqO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRwMESzPVkh|ryP NGjlSY1USU6JRWK=
SW1990 NHr5SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRwMEW5NFgh|ryP NXnWd|RFW0GQR1XS
LK-2 NX\jdnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\RPItKSzVyPUSuNVEzQTNizszN NX\IO2RoW0GQR1XS
ES5 NYK5W3JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTXTWM2OD12LkGzPVg2KM7:TR?= NVXo[5RWW0GQR1XS
JVM-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnybVJKSzVyPUSuNVgzOjJizszN MorGV2FPT0WU
RPMI-7951 M{f3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLydJBKSzVyPUSuNlI1OTNizszN NILGPIxUSU6JRWK=
Calu-6 M3rzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHyc4JKSzVyPUSuNlc5QDFizszN M3jXenNCVkeHUh?=
LC-2-ad Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TrR2lEPTB;ND6yPVU3QCEQvF2= MnHIV2FPT0WU
SW954 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\GTWM2OD12LkK5OlYh|ryP MYXTRW5ITVJ?
H-EMC-SS NYrueZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2wTWM2OD12LkOxPFMyKM7:TR?= NHTwWYRUSU6JRWK=
ES3 NU[1XIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn71TWM2OD12LkO1OFQyKM7:TR?= M1\BNXNCVkeHUh?=
no-11 M4ftR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;ETWM2OD12LkO1OVU1KM7:TR?= NXHsVXltW0GQR1XS
LAN-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\4T2tKSzVyPUSuOFUyQDlizszN M1TOfnNCVkeHUh?=
FTC-133 NVrBXo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHOdZlPUUN3ME20MlU{QTVizszN MmCyV2FPT0WU
8505C NGDLXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\4TWM2OD12LkW0NlMh|ryP MoLEV2FPT0WU
SW620 NVTXcnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3TWM2OD12LkW3NFU4KM7:TR?= NILDe|dUSU6JRWK=
BCPAP MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0dpp[UUN3ME20MlY{PDhzIN88US=> NUO2T2ZoW0GQR1XS
SK-LU-1 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwNk[wPFkh|ryP M1HDOnNCVkeHUh?=
NCI-H1623 NFfYWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TW[WlEPTB;ND63NFIzQCEQvF2= M3X0cHNCVkeHUh?=
C2BBe1 NVTQVXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTRwN{SwNFgh|ryP NGn5[5JUSU6JRWK=
GP5d MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwN{izPFgh|ryP MVTTRW5ITVJ?
NB6 NHXJdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHZ[pRKSzVyPUSuPFYzODRizszN NIXEPIVUSU6JRWK=
MDA-MB-157 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWyepp6UUN3ME20Mlg5PzZizszN MWPTRW5ITVJ?
UMC-11 M1vIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXITWM2OD12Lki4PVY1KM7:TR?= NF;GSGhUSU6JRWK=
HCC1419 NWDDd2hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W0UmlEPTB;ND65NFA3OyEQvF2= MlH6V2FPT0WU
NCI-H2029 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwOUSxPFUh|ryP NYXKN29KW0GQR1XS
LXF-289 NImyUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTVwMEO3NVkh|ryP NGC3PVJUSU6JRWK=
KINGS-1 NEDUbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwMEe3OFQh|ryP NInmUJBUSU6JRWK=
HD-MY-Z NVvuUI44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTVwMkO5Olkh|ryP M1\WTXNCVkeHUh?=
ESS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTVwMkW1PVch|ryP NUfK[mVLW0GQR1XS
GI-1 NWO5OItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInqOGVKSzVyPUWuNlc6OjZizszN NULoXVd1W0GQR1XS
RPMI-2650 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfITWM2OD13LkO2NVYh|ryP MkjiV2FPT0WU
IA-LM NHvyOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\mT2lEPTB;NT6zPVg4OSEQvF2= MUTTRW5ITVJ?
KP-4 NWPz[HdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrXTHV[UUN3ME21MlQ3OzN2IN88US=> NUG3S483W0GQR1XS
G-402 NETnS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e0OWlEPTB;NT61NVg3PSEQvF2= NYDaUIZ{W0GQR1XS
OS-RC-2 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwNUK2NFQh|ryP NHyyTY9USU6JRWK=
NCI-H1155 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHrTWM2OD13LkW0PVU2KM7:TR?= MXzTRW5ITVJ?
OE19 MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TqV2lEPTB;NT62PFYzPCEQvF2= MnLiV2FPT0WU
U-2-OS NFLXPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHLTWM2OD13Lki5NFE{KM7:TR?= M4HsSnNCVkeHUh?=
SCC-15 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fHSWlEPTB;NT65N|Y3OiEQvF2= NYraNZM6W0GQR1XS
NCI-H630 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnztTWM2OD13Lkm5OFA1KM7:TR?= MV;TRW5ITVJ?
PFSK-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT3TWM2OD14LkC1NlU6KM7:TR?= NH;LfZdUSU6JRWK=
NCI-H1770 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PYNGlEPTB;Nj6yNFg4PCEQvF2= M2PhZnNCVkeHUh?=
SK-MEL-3 NWCxTYlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOxSVRKSzVyPU[uOFI6OTVizszN NUjNenl6W0GQR1XS
LB1047-RCC M13QeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTZwNEe2NlUh|ryP M2P3TnNCVkeHUh?=
NCI-H446 M3raXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHwVms2UUN3ME22MlYzQTJ3IN88US=> MXnTRW5ITVJ?
SW780 NX\lWGpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmexTWM2OD14LkewNVg2KM7:TR?= NG\RVYVUSU6JRWK=
NEC8 NXHGbGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZwN{[2N{DPxE1? MXXTRW5ITVJ?
NOMO-1 NVSwdHJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Pe24xUUN3ME22Mlc5OTFzIN88US=> NWHu[VFjW0GQR1XS
COLO-668 NGXSbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHraR4hKSzVyPU[uPFQ{QDdizszN NHLXXIhUSU6JRWK=
MC116 NWHLO5o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPHcIRKSzVyPU[uPVM5QTdizszN MULTRW5ITVJ?
HCC1937 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjTTWM2OD14Lkm5NlUyKM7:TR?= MUjTRW5ITVJ?
NCI-N87 NXTmNJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTdwMUmyPVMh|ryP NVvwc2hpW0GQR1XS
COLO-320-HSR NFPrcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrhXnNUUUN3ME23MlIzPzN6IN88US=> NX;GZoxuW0GQR1XS
HCC1806 NEHuclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12zb2lEPTB;Nz6yOlA1PCEQvF2= NV:xfno4W0GQR1XS
OVCAR-3 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fzXGlEPTB;Nz6zN|A{QCEQvF2= NVzBOIRPW0GQR1XS
NUGC-3 NHLn[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTdwM{m2PVQh|ryP MWjTRW5ITVJ?
SW1783 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPYWodRUUN3ME23MlQ{OTd3IN88US=> NX7GUXhRW0GQR1XS
GCT MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTdwNU[5NFYh|ryP NX\wXph5W0GQR1XS
NCI-H2126 NV7kb4lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\jTmlEPTB;Nz63N|YzPSEQvF2= MmrXV2FPT0WU
MEL-HO M4DKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXmcWtPUUN3ME23Mlc4ODV2IN88US=> MWfTRW5ITVJ?
CAPAN-1 NXPZ[VNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zUPGlEPTB;Nz63O|M2PyEQvF2= NEnYeFFUSU6JRWK=
SW756 NIDJSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfXTWM2OD15Lke4N|M{KM7:TR?= NX;uT2NoW0GQR1XS
SKG-IIIa NUS4RYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwOEG4PVIh|ryP Mm\kV2FPT0WU
HCE-T M1qy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrKTWM2OD15Lki3O|g{KM7:TR?= NX[2cmF6W0GQR1XS
Ca-Ski M3jHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn3OmtxUUN3ME23Mlk6Ozh|IN88US=> MVHTRW5ITVJ?
COLO-684 M1Ha[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRThwMEG4NVgh|ryP MnjHV2FPT0WU
KYSE-70 M3rpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XpR2lEPTB;OD6wO|czQSEQvF2= MWHTRW5ITVJ?
TI-73 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSxdndKSzVyPUiuNlU5PTFizszN Mme5V2FPT0WU
BT-20 NYTIPVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRThwMk[wOVIh|ryP MmHLV2FPT0WU
MHH-ES-1 NELPVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rZbmlEPTB;OD61NVg{PCEQvF2= MYXTRW5ITVJ?
TE-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTyW2pEUUN3ME24MlU6QTNzIN88US=> MYTTRW5ITVJ?
YH-13 NWr5c3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2wNnBGUUN3ME24MlYyODB6IN88US=> NIjCOWdUSU6JRWK=
SF126 NELSdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz6d2Z{UUN3ME24Mlg{QDZ3IN88US=> M1zzW3NCVkeHUh?=
J82 NVjO[5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKwT2w3UUN3ME24MlkxODN6IN88US=> MWXTRW5ITVJ?
RCC10RGB NXjCT|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jr[GlEPTB;OD65PVU3OSEQvF2= MknNV2FPT0WU
SK-UT-1 M2nxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDLWHpKSzVyPUmuNFQ6PDVizszN MmnUV2FPT0WU
LB2241-RCC M3\KfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PmNmlEPTB;OT6xPVE{PyEQvF2= NHPidFVUSU6JRWK=
LB996-RCC NFnkdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTwW4lKSzVyPUmuNVk5QSEQvF2= M1fyfXNCVkeHUh?=
EPLC-272H MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLPWlEPTB;OT6zO|Y2PyEQvF2= MkK0V2FPT0WU
CTV-1 NHjLVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHENFd[UUN3ME25MlU3PTN{IN88US=> Ml;TV2FPT0WU
HSC-2 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXwXplKSzVyPUmuOVc2PSEQvF2= M37VenNCVkeHUh?=
SK-MEL-28 M3PZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDWUmhKSzVyPUmuOlE5QTNizszN MlnlV2FPT0WU
MMAC-SF NV;4enJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\P[GZKSzVyPUmuOlg4PSEQvF2= M2exSHNCVkeHUh?=
CP50-MEL-B M4CzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTFdZJEUUN3ME25Mlc2Pzh{IN88US=> MmHBV2FPT0WU
HT-1080 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfUUYtZUUN3ME25Mlc4PzN7IN88US=> NXfwWZN1W0GQR1XS
HEC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHCZYZKSzVyPUGwMlM{PTJizszN NHGyc|JUSU6JRWK=
AGS MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFyLkO3OEDPxE1? NY\l[4hQW0GQR1XS
GAMG M1yxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjaSGtKSzVyPUGwMlUyPjJizszN Mn3YV2FPT0WU
SW48 M17Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;VTWM2OD1zMD61NVg6KM7:TR?= M2rIW3NCVkeHUh?=
U031 NXO1cI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPzTWM2OD1zMD61PVA5KM7:TR?= MY\TRW5ITVJ?
OVCAR-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInTO3hKSzVyPUGwMlY1OjlizszN NH\DR2pUSU6JRWK=
SF295 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7sToNPUUN3ME2xNE43PzB2IN88US=> NGfqU|ZUSU6JRWK=
BHT-101 NUjY[JM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjTTZFlUUN3ME2xNE44OTd5IN88US=> MY\TRW5ITVJ?
VMRC-RCZ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[0S3NqUUN3ME2xNU4{OjBzIN88US=> M2\uS3NCVkeHUh?=
ACHN MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTvXlVmUUN3ME2xNU41OjFzIN88US=> NGDoOotUSU6JRWK=
NCI-H526 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFzLkWwOFMh|ryP NWruRYZCW0GQR1XS
MN-60 NFPhd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXhe|VKSzVyPUGxMlU{QSEQvF2= MXXTRW5ITVJ?
NCI-H2291 M4SwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tb2lEPTB;MUGuOVQ3PiEQvF2= M4\TOXNCVkeHUh?=
SCC-25 M4C1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjtRohRUUN3ME2xNU44PTV4IN88US=> NFW1VndUSU6JRWK=
SK-MEL-2 NETQO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j4WGlEPTB;MUGuO|Y{PyEQvF2= NFq5[mhUSU6JRWK=
SN12C NELhSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fW[mlEPTB;MUGuPVM2PSEQvF2= MljrV2FPT0WU
NCI-H69 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Oe3FlUUN3ME2xNk41OjN2IN88US=> MnS5V2FPT0WU
ME-180 M4P5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF{LkewOVQh|ryP MoK5V2FPT0WU
MC-IXC M2C5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzndVZKSzVyPUGyMlc2OThizszN NXTQXGRJW0GQR1XS
NCI-H2347 NVHtZWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;jPZJCUUN3ME2xNk44PjF2IN88US=> MkizV2FPT0WU
M059J NVPtenU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXicGFKSzVyPUGyMlc4OjdizszN NVTBTIFwW0GQR1XS
A2058 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzYS|BKSzVyPUGyMlg3QDFizszN M3WyT3NCVkeHUh?=
VA-ES-BJ NEHycWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuyXmpKSzVyPUGyMlg4QDVizszN MUXTRW5ITVJ?
Ca9-22 M1XxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLsfZNKSzVyPUGyMlk1PTFizszN NF;sV49USU6JRWK=
KNS-42 NGLEfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTXTWM2OD1zMj65PVg1KM7:TR?= MVPTRW5ITVJ?
LoVo MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXeyWlZkUUN3ME2xN{4zOzF|IN88US=> MkPxV2FPT0WU
AM-38 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXke|JKSzVyPUGzMlI2PjZizszN MYfTRW5ITVJ?
NB5 NY\Ub3dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[xO2lEPTB;MUOuN|c2OiEQvF2= MV;TRW5ITVJ?
L-363 NGK5c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF|LkSwN|Mh|ryP M{[yR3NCVkeHUh?=
SK-MEL-30 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoeyTWM2OD1zND6wOlQ2KM7:TR?= NXXaT2tGW0GQR1XS
NCI-H1563 NWDLdpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTGTWM2OD1zND62NFM6KM7:TR?= MnHPV2FPT0WU
NCI-H2228 NH71N|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r6emlEPTB;MUSuOlA4PyEQvF2= MXPTRW5ITVJ?
MFM-223 NV64XYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF3LkG4NVMh|ryP MUXTRW5ITVJ?
LB831-BLC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHmPFJQUUN3ME2xOU4zPzZ5IN88US=> MX7TRW5ITVJ?
SW872 M1nrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGwTWM2OD1zNT6zNFg3KM7:TR?= NV:5e|RjW0GQR1XS
NCI-H522 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XKU2lEPTB;MUWuN|MxPiEQvF2= MXXTRW5ITVJ?
EW-1 M1jXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD1zNT61OFYzKM7:TR?= M2PJ[nNCVkeHUh?=
HN MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[0Vm5KSzVyPUG1MlU6PDJizszN Ml;HV2FPT0WU
SW837 M3X1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;KSmZKSzVyPUG1Mlc5PDdizszN MYHTRW5ITVJ?
SCC-9 M17i[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorVTWM2OD1zNT64NVE1KM7:TR?= M1;OWXNCVkeHUh?=
MKN7 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF3Lkm3N|Ih|ryP NGL0eXZUSU6JRWK=
KYSE-410 M1HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLKTWM2OD1zNj61PVEh|ryP MkH0V2FPT0WU
SK-N-DZ NUPNNWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF4Lk[xNVYh|ryP M3Pj[HNCVkeHUh?=
COR-L105 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nveWlEPTB;MU[uOlUzQCEQvF2= M161U3NCVkeHUh?=
LB2518-MEL NXHlfnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvqNYZtUUN3ME2xOk45Ozh7IN88US=> M1jsSnNCVkeHUh?=
OVCAR-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF4Lki4OlIh|ryP NGTSPGlUSU6JRWK=
TK10 NHHSToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF4Lkm0O|Mh|ryP MnW0V2FPT0WU
KNS-62 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF4Lkm3O|ch|ryP M3zvRnNCVkeHUh?=
RPMI-8866 M1fZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;hZo51UUN3ME2xO{4yPzN{IN88US=> M4jpeXNCVkeHUh?=
HuP-T4 NX;OUHJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXsTWM2OD1zNz6yOFk2KM7:TR?= NYnUc|FoW0GQR1XS
CGTH-W-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF5LkWyNVkh|ryP MUTTRW5ITVJ?
T-24 NGfPNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\xb5VKSzVyPUG3MlU{PDdizszN MlS0V2FPT0WU
HT-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF5LkW5NVQh|ryP MVnTRW5ITVJ?
KS-1 NHPpUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF5Lk[3N{DPxE1? M{ToenNCVkeHUh?=
NCI-H1792 M3jNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF5Lke5PEDPxE1? M1n0bHNCVkeHUh?=
ABC-1 NHzmXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPNeGdKSzVyPUG3MlgyPDFizszN MX7TRW5ITVJ?
BPH-1 NWHzcYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z5bmlEPTB;MUiuNVY5PSEQvF2= Mn25V2FPT0WU
A431 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[wTWM2OD1zOD60NVI4KM7:TR?= Ml7UV2FPT0WU
T98G NWDVRlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLuOopPUUN3ME2xPE42OTV5IN88US=> MojiV2FPT0WU
BHY M3TvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG0NIpKSzVyPUG4Mlg3QSEQvF2= NFT0TlJUSU6JRWK=
Capan-2 M{G1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn63TWM2OD1zOD65NFc5KM7:TR?= M1nxWnNCVkeHUh?=
MDA-MB-175-VII NYK2RVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLaTWM2OD1zOD65NlA6KM7:TR?= MVLTRW5ITVJ?
CAL-27 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF7LkC0PFch|ryP MYPTRW5ITVJ?
AsPC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnw[mtHUUN3ME2xPU45PjV5IN88US=> NGjEXlJUSU6JRWK=
KU812 NW\BXlZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnSU25KSzVyPUG5Mlk2PzNizszN NEDXV|BUSU6JRWK=
NCI-H441 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LEO2lEPTB;MkCuNFAyKM7:TR?= NX2zSG9kW0GQR1XS
Mewo M2T0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37WemlEPTB;MkCuNVI5QCEQvF2= MmTmV2FPT0WU
SK-MEL-24 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvVZW1KSzVyPUKwMlE1PzdizszN M{XpfHNCVkeHUh?=
NCI-H727 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLDTWM2OD1{MD6yO|A1KM7:TR?= MYrTRW5ITVJ?
EKVX M1:xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\6d4FZUUN3ME2yNE43ODZizszN NF:zWJVUSU6JRWK=
RT-112 NGjTZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DaZWlEPTB;MkCuOlEzOiEQvF2= MnjGV2FPT0WU
CAMA-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\KOGMzUUN3ME2yNE46QDB|IN88US=> NYi5Z4FsW0GQR1XS
SW900 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJzLkCxOFkh|ryP Mo\VV2FPT0WU
NCI-H23 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXhTWM2OD1{MT6xNlc4KM7:TR?= Mk\QV2FPT0WU
SK-PN-DW M2\MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTWdIR3UUN3ME2yNU4yPjR7IN88US=> MlvTV2FPT0WU
BB30-HNC M3q4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzfWRKSzVyPUKxMlI4PDVizszN NYnyUGxyW0GQR1XS
VM-CUB-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJzLkO1N|Yh|ryP MXzTRW5ITVJ?
IST-MEL1 NYDib5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkToTWM2OD1{MT6zOlkzKM7:TR?= MkDZV2FPT0WU
CTB-1 NEXJ[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJzLkS3OVUh|ryP M2jJcHNCVkeHUh?=
LCLC-103H NEjhOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LrfmlEPTB;MkKuNVU5OiEQvF2= NVP5XWlQW0GQR1XS
PANC-03-27 M33BUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jLNmlEPTB;MkKuOVE3QSEQvF2= NF35cI5USU6JRWK=
HTC-C3 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHaNG9KSzVyPUKyMlU2PTVizszN MofpV2FPT0WU
TE-8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ|LkK1OlUh|ryP NHTRdYJUSU6JRWK=
NCI-H292 NVnjdpJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLKTWM2OD1{NT6zOVM3KM7:TR?= M3vMNHNCVkeHUh?=
COLO-680N Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDETWM2OD1{NT62N|I6KM7:TR?= NFLie4hUSU6JRWK=
KYSE-520 NWiwd2htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV35dIlpUUN3ME2yOU43PDRizszN NHrGZ3pUSU6JRWK=
NB10 NHLvOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjiTJNZUUN3ME2yOk4{OTF5IN88US=> M2Hw[3NCVkeHUh?=
NCI-H661 NV:1RVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ4LkS3NVMh|ryP MVvTRW5ITVJ?
GMS-10 M2r3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnyZo1KSzVyPUK2Mlg3OzhizszN NHG2NppUSU6JRWK=
NCI-H2122 NEPIfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn3bm81UUN3ME2yOk46QTl6IN88US=> NYXvVGdRW0GQR1XS
OVCAR-8 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHSeo1KSzVyPUK3MlA3OzhizszN M2C5d3NCVkeHUh?=
DJM-1 NYLaZ3pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHETppSUUN3ME2yO{4yPDV2IN88US=> MW\TRW5ITVJ?
UACC-893 M3;zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fRSGlEPTB;MkeuPVg4QCEQvF2= MXvTRW5ITVJ?
C8166 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzFTWM2OD1{OD62PVM5KM7:TR?= NYPqSJR4W0GQR1XS
NCI-H1693 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD0T5h2UUN3ME2yPE43QTd3IN88US=> MUnTRW5ITVJ?
TYK-nu NVz1Xox3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml36TWM2OD1|MD6wN|Q2KM7:TR?= NWT3[GRQW0GQR1XS
SW1710 NHrEfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS0ZoJQUUN3ME2zNE4yOjZizszN M{T1SXNCVkeHUh?=
A375 NEHoS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHJW|dKSzVyPUOwMlMzPDNizszN NF\sN5dUSU6JRWK=
HMV-II MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv5O|RuUUN3ME2zNU4{PTl{IN88US=> M1HNcHNCVkeHUh?=
NCI-H2087 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\rdWlEPTB;M{GuOlM2OiEQvF2= NWfoO2I5W0GQR1XS
CAL-54 M2jyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNzLkeyOFEh|ryP Mk[xV2FPT0WU
HCC70 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nBdGlEPTB;M{KuNVM5PyEQvF2= NFfGXmxUSU6JRWK=
ES1 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzCTWM2OD1|Mj6zNFYzKM7:TR?= MnnvV2FPT0WU
NCI-H1355 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN|LkKwOEDPxE1? NEXFPGpUSU6JRWK=
CFPAC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTNd3ZTUUN3ME2zN{4zOzN{IN88US=> MnTtV2FPT0WU
MKN28 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17WcmlEPTB;M{OuN|gxQSEQvF2= MnTEV2FPT0WU
HDLM-2 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H5N2lEPTB;M{OuOlk{OSEQvF2= MoPEV2FPT0WU
PANC-10-05 NHv6c4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPMb2NKSzVyPUO0MlExOTRizszN NXvWTW45W0GQR1XS
SAS NV3GN4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLrOYRKSzVyPUO0MlQ2PjVizszN NXPsTpZLW0GQR1XS
HCC1395 M3PYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S2fWlEPTB;M{SuO|E5PiEQvF2= MnjlV2FPT0WU
8305C NHPIUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HaWmlEPTB;M{WuPFQyPSEQvF2= NWDFepBYW0GQR1XS
KM12 NHjNXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN4Lke1OFch|ryP M2\VXnNCVkeHUh?=
SW1116 NYWy[Wx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\TXWlEPTB;M{euOVk6OiEQvF2= MXPTRW5ITVJ?
SK-MEL-1 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvDOWxKSzVyPUO4MlM{QDlizszN Ml7wV2FPT0WU
HCC2218 NVGybJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXtR3pxUUN3ME2zPE43PTF7IN88US=> M1z6Z3NCVkeHUh?=
T84 M1f1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKw[FRKSzVyPUO4Mlc1ODlizszN MlixV2FPT0WU
ETK-1 NX\PT4hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN7LkCyNkDPxE1? MWLTRW5ITVJ?
COLO-800 M2rRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\kXmlEPTB;M{muN|g3QCEQvF2= MVjTRW5ITVJ?
CAL-12T M4rUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;3PYV5UUN3ME2zPU42OjhzIN88US=> MX;TRW5ITVJ?
ACN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWyTWM2OD12MD60PVEyKM7:TR?= NXmySmN7W0GQR1XS
SJSA-1 NVrvZZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;YTWM2OD12MT6xOVk3KM7:TR?= M3rTTHNCVkeHUh?=
PSN1 M2fWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLIW|VKSzVyPUSxMlE4PDlizszN MV;TRW5ITVJ?
D-566MG NXHofmZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CyTWlEPTB;NEGuNlA5PiEQvF2= MV3TRW5ITVJ?
EGI-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR{LkSyPEDPxE1? NEH3PFhUSU6JRWK=
A204 M3TOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTR{Lk[zPFgh|ryP M{PtNXNCVkeHUh?=
Saos-2 M{SxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXrTJNYUUN3ME20Nk45OzZ7IN88US=> MXTTRW5ITVJ?
SNU-C2B M3PmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrCTWM2OD12Mz62PFc5KM7:TR?= NI\QfIFUSU6JRWK=
HLE MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP3TWM2OD12ND6wPFU3KM7:TR?= MkX4V2FPT0WU
SW1463 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBOGlEPTB;NESuPVk4OSEQvF2= MoLaV2FPT0WU
DSH1 NIjhVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR3LkCwN|Mh|ryP M{jsc3NCVkeHUh?=
MCF7 NH74Z4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfLTWM2OD12NT61NFUyKM7:TR?= M4r5SnNCVkeHUh?=
K5 NXrST49nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfL[nlkUUN3ME20OU46PDB3IN88US=> MljQV2FPT0WU
NCI-H358 M3HmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR5LkKxOUDPxE1? NGDScZFUSU6JRWK=
NCI-H2030 M3joe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\OdIVpUUN3ME20O{4zOzd2IN88US=> MkDvV2FPT0WU
SW948 M1LT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXTVm5KUUN3ME20O{41PjRizszN NU\xPVZCW0GQR1XS
BALL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDBPYdLUUN3ME20O{43OTZ6IN88US=> MoK4V2FPT0WU
TE-9 NFLu[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR5Lkm1PFEh|ryP MmO4V2FPT0WU
SK-N-FI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4[mlEPTB;NEiuNFM2QCEQvF2= MVHTRW5ITVJ?
KALS-1 NUfnUHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17GRWlEPTB;NEiuNVI5QSEQvF2= NGrZTZJUSU6JRWK=
HO-1-N-1 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR6Lke0OFUh|ryP MkTvV2FPT0WU
NCI-H2452 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjxUVVKSzVyPUS5MlEyPTJizszN Mn:3V2FPT0WU
OC-314 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR7Lk[4N|Qh|ryP MW\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

- Collapse
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03181126 Active not recruiting Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Active not recruiting Drug: Navitoclax|Drug: Osimertinib Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Drug: ABT-263 Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02079740 Recruiting Biological: Navitoclax|Drug: Trametinib Advanced Lung Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Pancreatic Carcinoma|Malignant Female Reproductive System Neoplasm|Metastatic Malignant Solid Neoplasm|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax|Navitoclax ic50|Navitoclax price|Navitoclax cost|Navitoclax solubility dmso|Navitoclax purchase|Navitoclax manufacturer|Navitoclax research buy|Navitoclax order|Navitoclax mouse|Navitoclax chemical structure|Navitoclax mw|Navitoclax molecular weight|Navitoclax datasheet|Navitoclax supplier|Navitoclax in vitro|Navitoclax cell line|Navitoclax concentration|Navitoclax nmr|Navitoclax in vivo|Navitoclax clinical trial|Navitoclax inhibitor|Navitoclax Apoptosis inhibitor|Navitoclax does
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID